BioLineRx (NASDAQ:BLRX) Shares Cross Above Two Hundred Day Moving Average – Here’s What Happened

Posted by ABMN Staff on Jun 27th, 2026

BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.87 and traded as high as $3.29. BioLineRx shares last traded at $3.16, with a volume of 6,025 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Get Our Latest Analysis on BioLineRx

BioLineRx Stock Up 1.3%

The stock has a market capitalization of $13.81 million, a price-to-earnings ratio of -1.65 and a beta of 1.53. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.58 and a quick ratio of 1.43. The business has a fifty day moving average of $3.02 and a 200 day moving average of $2.87.

BioLineRx (NASDAQ:BLRX – Get Free Report) last posted its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.68. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The company had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $0.34 million.

BioLineRx Company Profile

(Get Free Report)

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.